Safety aspects

 


 

Patients with MS seen in clinical practices are more likely to be older, affected by co-morbidities or other risk factors than those assessed in clinical studies [1,2]. With older age, co-morbidities, smoking or obesity, the clinical vulnerability of people may increase [3-5]. For instance, older individuals may not respond to immune challenges as robustly as the young, which may make them more vulnerable to infections or cancer [6,7]. Betaferon has neither been associated with signals of cancer nor with an increased risk of infections [8-13].

 

Substantial datasets confirm its benefit-to-risk profile over the long-term [14] and the use of Betaferon is supported by more than 25 years of clinical use [15] adding up to over 1.7 million patient-years of experience [16].

 

References

Alt tag